Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
11 August 2020 - 6:17AM
Edgar (US Regulatory)
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
|
|
|
(Check one):
|
|
☐ Form
10-K
|
☐ Form
20-F
|
☐ Form
11-K
|
☒ Form
10-Q
|
☐ Form
10-D
|
|
|
☐ Form
N-CEN
|
☐ Form
N-CSR
|
|
|
|
|
|
|
|
|
|
|
|
|
For
Period Ended:
|
June
30, 2020
|
|
|
☐ Transition
Report on Form 10-K
|
|
|
|
|
☐ Transition
Report on Form 20-F
|
|
|
|
|
☐ Transition
Report on Form 11-K
|
|
|
|
|
☐ Transition
Report on Form 10-Q
|
|
|
|
|
For the
Transition Period Ended:
|
|
Read Instruction (on back page) Before Preparing Form. Please Print
or Type.
Nothing in this form shall be construed to imply that the
Commission has verified any information contained
herein.
|
If the
notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification relates:
PART I — REGISTRANT INFORMATION
Cellular Biomedicine Group, Inc.
|
Full
Name of Registrant
|
|
Not Applicable
|
Former
Name if Applicable
|
|
209 Perry Parkway, Suite 13
|
Address
of Principal Executive Office (Street and Number)
|
|
Gaithersburg, MD 20877
|
City,
State and Zip Code
|
PART II — RULES 12b-25(b) AND (c)
If the
subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to
Rule 12b-25(b), the following should be completed. (Check box
if appropriate)
|
(a)
|
The
reason described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or
expense;
|
☒
|
(b)
|
The
subject annual report, semi-annual report, transition report on
Form 10-K, Form 20-F, Form 11-K, Form N-CEN or
Form N-CSR, or portion thereof, will be filed on or before the
fifteenth calendar day following the prescribed due date; or the
subject quarterly report or transition report on Form 10-Q or
subject distribution report on Form 10-D, or portion thereof,
will be filed on or before the fifth calendar day following the
prescribed due date; and
|
|
(c)
|
The
accountant’s statement or other exhibit required by
Rule 12b-25(c) has been attached if applicable.
|
PART III — NARRATIVE
State
below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q,
10-D, N-CEN, N-CSR, or the transition report or portion thereof,
could not be filed within the prescribed time period.
Cellular
Biomedicine Group, Inc. (“CBMG” or the
“Company”) has determined that it is unable to file its
Quarterly Report on Form 10-Q for the fiscal quarter ended
June 30, 2020 (the “Form 10-Q”) within the prescribed
period without unreasonable effort or expense because it is still
finalizing its description of recent developments with regard to
subsequent events in the Form 10-Q. The Company anticipates that it
will file the Form 10-Q as soon as reasonably possible and within
the 5-day grace period provided by Rule 12b-25 of the
Securities Exchange Act of 1934, as amended.
PART IV — OTHER INFORMATION
(1)
|
Name
and telephone number of person to contact in regard to this
notification
|
|
Andrew Chan
|
|
301
|
|
825-5320
|
|
(Name)
|
|
(Area
Code)
|
|
(Telephone
Number)
|
|
|
(2)
|
Have
all other periodic reports required under Section 13 or 15(d) of
the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such
shorter period that the registrant was required to file such
report(s) been filed? If answer is no, identify
report(s).
|
|
|
|
|
|
|
|
☒ Yes ☐ No
|
|
|
|
|
|
|
(3)
|
Is it
anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject
report or portion thereof?
|
|
|
|
|
|
|
|
☐ Yes ☒ No
|
|
|
|
|
|
|
|
If so,
attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a
reasonable estimate of the results cannot be made.
|
|
|
|
Cautionary Note Regarding Forward-Looking Statements
This
Form 12b-25 contains forward-looking statements, including, without
limitation, statements regarding CBMG’s expectations as to
the filing of the Form 10-Q and the presentation of subsequent
events. Forward-looking information is inherently subject to risks
and uncertainties, and actual results could differ materially from
those currently anticipated due to a number of factors, which
include any risks detailed from time to time in CBMG’s
reports filed with the Securities and Exchange Commission,
including risks relating to the impact of the COVID-19 pandemic on
our operations. These statements reflect our current views with
respect to future events or to our future activities and involve
known and unknown risks, uncertainties and other factors which may
cause our actual activities, actions or achievements to be
materially different from any future activities, actions or
achievements expressed or implied by the forward-looking
statements. Given these uncertainties, you should not place undue
reliance on these forward-looking statements.
|
Cellular Biomedicine Group, Inc.
(Name
of Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the
undersigned hereunto duly authorized.
Date
|
August
10, 2020
|
|
By
|
/s/
Andrew Chan
|
|
|
|
|
Andrew Chan
Chief Legal Officer (General
Counsel),
Corporate Development and Secretary
|
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Apr 2024 to May 2024
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Cellular Biomedicine Group Inc (NASDAQ): 0 recent articles
More Cellular Biomedicine Group, Inc. News Articles